CA-based Zafrens Secures $23M in Funding. Prime Movers Lab spearheaded the funding round, with additional participation from investors such as BlueYard Capital, KOFA Healthcare, Global Brains, FoundersX Ventures, Possible Ventures, Iaso Ventures, Hawktail, and others.

The funds will be utilised by the business to create an internal pipeline and maximise ground-breaking Z-ScreenTM platform applications.

Read also – MO-based Simplifield E-Solutions Secures an Investment from HCAP

Zafrens is an ultra-high throughput platform that can isolate, cultivate, photograph, and sequence millions of cells every day. It is led by CEO Swamy Vijayan. The unique platform makes it possible to fully characterise a wide range of cell populations and establish a direct correlation among the function and phenotype of cells and their molecular profiles (DNA, RNA, and protein).

The Z-ScreenTM expands the traditional 96-well format to 50,000–200,000 wells with imaging and single-cell multi-omic capabilities encompassed in every well, signalling a boost in experiment throughput and resolution. It is now possible to simultaneously resolve complex cellular co-culture interactions at the molecular and functional levels.

Read also – PA-based Geo-Solutions Secures an Investment from Blue Sage Capital

It is possible to map the distinct manifestations of large CRISPR, CAR-T, mRNA libraries, and endogenous molecular heterogeneity, such as cell behaviour, cell-cell connections, and secretions.

Zafrens is seeking to collaborate with partners in its own domains of expertise, which include highly selective, HLA-independent TCR discovery and RNA regulatory small molecules related to 3′ UTR control, splicing, and epigenetic reprogramming, after streamlining and industrialising Z-Screens.

The company is looking for more partnerships in these areas, as well as other areas where combinatorial libraries of small-molecules, genetic perturbations, and/or cell-cell interactions could lead to breakthroughs, having already proven transformative capabilities in CAR-T optimisation and bi-specifics discovery.

Read also – Colombian Fintech Startup Supra Secures an Undisclosed Amount in Funding

About Zafrens

A pharmaceuticals startup called Zafrens is developing a technology for ultra-high throughput that allows it to isolate, cultivate, photograph, and sequence millions of cells every day.

Read also – Canada-based Durable Secures $14M in Series A Round Funding

The exclusive platform makes it possible to fully characterise a wide range of cell populations and establish a direct correlation between the function and phenotype of cells and their molecular profiles (DNA, RNA, and protein).